Clinical trial
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for…
NCT00333008 · The Alvin and Lois Lapidus Cancer Institute, Other · Unknown status
Key facts
| NCT number | NCT00333008 |
|---|---|
| Title | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. |
| Official title | Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status |
| Lead sponsor | The Alvin and Lois Lapidus Cancer Institute, Other |
| Collaborators | Ortho Biotech Products, L.P. Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Doxil, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Pegfilgrastim |
| Enrollment | 27 |
| Start date | May 1, 2006 |
| First posted | Jun 2, 2006 |
| Last update posted | Sep 26, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: